CD274 and gastric cancer: In a previous pembrolizumab clinical trial targeting PDL1, the tumors in more than 50% of patients with advanced stage GC shrunk from baseline, highlighting the promising outcomes associated with GC immunotherapy (Matsueda and Graham, 2014).